share_log

华源证券4月25日发布研报称，给予恒瑞医药（600276.SH）买入评级。评级理由主要包括：1）国内医药龙头药企，迎全面创新转型新周期；2）集采压力基本调整完毕；3）创新研发管线布局全面，或迎新一轮收获期。（每日经济新闻）

Huayuan Securities released a research report on April 25 stating that it gave Hengrui Pharmaceutical (600276.SH) a purchase rating. The main reasons for the rating include: 1) leading domestic pharmaceutical companies entering a new cycle of comprehensiv

Zhitong Finance ·  Apr 25 17:37
Huayuan Securities released a research report on April 25 stating that it gave Hengrui Pharmaceutical (600276.SH) a purchase rating. The main reasons for the rating include: 1) leading domestic pharmaceutical companies entering a new cycle of comprehensive innovation and transformation; 2) collection pressure has been basically adjusted; 3) the innovative R&D pipeline layout is comprehensive, or welcoming a new harvest period. (Mainichi Keizai Shimbun)

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment